Exploring the potential of HVJ-E for cancer immunotherapy
Open Access
- 9 July 2026
- journal article
- review article
- Published by Taylor & Francis in Immunotherapy
- p. 1-17
Abstract
1. 1.1. Cancer immunotherapy has emerged as a central strategy in cancer treatment, with immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR) T cell therapy demonstrating clinica...Keywords
Funding Information
- Japan Agency for Medical Research and Development (18cm0106341h0001)
- Japan Agency for Medical Research and Development (23ym0126809j0002)
- Japan Agency for Medical Research and Development (25ama221343h0001)
- JST Program forco-creating startup ecosystem (JPMJSF2319)
- Gunma Foundation for Medicine and Health Science (24H00633)
- Takahashi Industrial and Economic Research Foundation
This publication has 90 references indexed in Scilit:
- In Situ Vaccines in the Era of Cancer Immunotherapy: Conceptual Innovation and Clinical TranslationAdvanced Science, 2025
- Viral vector‐based cancer treatment and current clinical applicationsMedComm – Oncology, 2023
- Type IIFNs induce anti‐tumor polarization of tumor associated neutrophils in mice and humanInternational Journal of Cancer, 2015
- IPS‐1 plays a dual function to directly induce apoptosis in murine melanoma cells by inactivated Sendai virusInternational Journal of Cancer, 2013
- Sterile alpha motif containing domain 9 is involved in death signaling of malignant glioma treated with inactivated Sendai virus particle (HVJ‐E) or type I interferonInternational Journal of Cancer, 2009
- Efficient eradication of hormone‐resistant human prostate cancers by inactivated Sendai virus particleInternational Journal of Cancer, 2009
- Central role of interferon regulatory factor‐1 (IRF‐1) in controlling retinoic acid inducible gene‐I (RIG‐I) expressionJournal of Cellular Physiology, 2007
- Rad51 siRNA delivered by HVJ envelope vector enhances the anti‐cancer effect of cisplatinThe Journal of Gene Medicine, 2005
- Biocompatible polymer enhances the in vitro and in vivo transfection efficiency of HVJ envelope vectorThe Journal of Gene Medicine, 2005
- Induction of a Systemic Immune Response by a Polyvalent Melanoma-Associated Antigen DNA Vaccine for Prevention and Treatment of Malignant MelanomaMolecular Therapy, 2002